M. Sieuwerts, A.; A. Inda, M.; Smid, M.; van Ooijen, H.; van de Stolpe, A.; Martens, J.W.M.; Verhaegh, W.F.J.
ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. Cancers 2020, 12, 802.
https://doi.org/10.3390/cancers12040802
AMA Style
M. Sieuwerts A, A. Inda M, Smid M, van Ooijen H, van de Stolpe A, Martens JWM, Verhaegh WFJ.
ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. Cancers. 2020; 12(4):802.
https://doi.org/10.3390/cancers12040802
Chicago/Turabian Style
M. Sieuwerts, Anieta, Márcia A. Inda, Marcel Smid, Henk van Ooijen, Anja van de Stolpe, John W. M. Martens, and Wim F. J. Verhaegh.
2020. "ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen" Cancers 12, no. 4: 802.
https://doi.org/10.3390/cancers12040802
APA Style
M. Sieuwerts, A., A. Inda, M., Smid, M., van Ooijen, H., van de Stolpe, A., Martens, J. W. M., & Verhaegh, W. F. J.
(2020). ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. Cancers, 12(4), 802.
https://doi.org/10.3390/cancers12040802